最新ニュース  (OTC:RGFSS) 株価情報

News

O-I Glass Plans Installation Of Furnace Technology In Holzminden, Germany That Is Expected To Enhance Energy Efficiency And Reduce Emissions

PTON: 20% &#x7C; <a href="https://www.benzinga.com//node/43524346">Peloton shares are trading higher following a Q2 revenue beat.</a>
&nbsp;
TPR: 13% &#x7C; <a href="https://www.benzinga.com//node/43523679">Tapestry shares are trading higher after the company reported Q2 financial results and beat its sales estimate.</a>
&nbsp;
LIPO: 148% &#x7C; <a href="https://www.benzinga.com//node/43524573">Lipella Pharmaceuticals shares are trading higher after the company received FDA approval for an expanded access program for LP-310 in oral lichen planus.</a>

Movers

Trading Ideas

LIPO

PTON

Market-Moving News for February 6th

WIIM

Lipella Pharmaceuticals shares are trading higher after the company received FDA approval for an expanded access program for LP-310 in oral lichen planus.

Rosenblatt analyst Kevin Cassidy downgrades Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) from Buy to Neutral and lowers the price target from $120 to $80.

Downgrades

Price Target

Analyst Ratings

SWKS

Rosenblatt Downgrades Skyworks Solutions to Neutral, Lowers Price Target to $80

Piper Sandler analyst Alexander Goldfarb maintains Terreno Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Overweight and lowers the price target from $80 to $78.

TRNO

Piper Sandler Maintains Overweight on Terreno Realty, Lowers Price Target to $78

The purchase price represents a 66% premium to Altus Power's unaffected closing price on October 15, 2024, the last trading day prior to the Company's announcement of a formal review of strategic alternatives by its Board of Directors.

AMPS

Altus Power Says Company Entered Into Definitive Agreement To Be Acquired By TPG Through Its TPG Rise Climate Transition Infrastructure Strategy For $5.00 Per Share In An All-cash Transaction That Values The Company At Approximately $2.2B

Piper Sandler analyst Paul Newsome maintains Skyward Specialty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>) with a Overweight and lowers the price target from $58 to $57.

SKWD

Piper Sandler Maintains Overweight on Skyward Specialty, Lowers Price Target to $57

Piper Sandler analyst Paul Newsome maintains Kemper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMPR#NYSE">KMPR</a>) with a Overweight and raises the price target from $83 to $86.

KMPR

Piper Sandler Maintains Overweight on Kemper, Raises Price Target to $86

MATW

TSLA

Matthews International Says It Won Arbitration Against Tesla, Resumes Sales of Advanced Battery Electrode Technology

HII's Financial Outlook1 includes the following expectations:
<ul>
<li>Mid to long term5 HII revenue growth of 4%+</li>
<li>Mid to long term5 shipbuilding revenue2 growth of approximately 4%</li>
<li>Mid to long term5 Mission Technologies revenue growth of approximately 5%</li>
<li>FY25 shipbuilding revenue2 between $8.9 and $9.1 billion; expect shipbuilding operating margin2 between 5.5% and 6.5%</li>
<li>FY25 Mission Technologies revenue between $2.9 to $3.1 billion, Mission Technologies segment operating margin2 between 4.0% and 4.5%; and Mission Technologies EBITDA margin2 between 8.0% and 8.5%</li>
<li>FY25 free cash flow2,3 between $300 and $500 million</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td>FY25 Outlook1</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Shipbuilding Revenue2</td>
<td>$8.9B - $9.1B</td>
</tr>
<tr>
<td>Shipbuilding Operating Margin2</td>
<td>5.5% - 6.5%</td>
</tr>
<tr>
<td>Mission Technologies Revenue</td>
<td>$2.9B - $3.1B</td>
</tr>
<tr>
<td>Mission Technologies Segment Operating Margin2</td>
<td>4.0% - 4.5%</td>
</tr>
<tr>
<td>Mission Technologies EBITDA Margin2</td>
<td>8.0% - 8.5%</td>
</tr>
<tr>
<td>Operating FAS/CAS Adjustment</td>
<td>($43M)</td>
</tr>
<tr>
<td>Non-current State Income Tax Benefit/Expense4</td>
<td>~$0M</td>
</tr>
<tr>
<td>Interest Expense</td>
<td>($130M)</td>
</tr>
<tr>
<td>Non-operating Retirement Benefit</td>
<td>$191M</td>
</tr>
<tr>
<td>Effective Tax Rate</td>
<td>~21%</td>
</tr>
<tr>
<td>Depreciation &amp; Amortization</td>
<td>~$340M</td>
</tr>
<tr>
<td>Capital Expenditures</td>
<td>~4% of Sales</td>
</tr>
<tr>
<td>Free Cash Flow2, 3</td>
<td>$300M - $500M</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Huntington Ingalls Indus Sees FY2025 Sales $11.800B-$12.200B vs $12.10B Est

Biotech

Health Care

Financing

Offerings

General

MBIO

Mustang Bio Priced Its Public Offering Of 2.65M Shares, Series C-1 Warrants To Purchase Up To 2.65M Shares And Series C-2 Warrants To Purchase Up To 2.65M Shares At A Combined Public Offering Price Of $3.01 Per Share

Tapestry Sees FY25 EPS $4.85-$4.90 Vs $4.67 Estimate; Sees Revenue $6.85B Vs $6.758B Estimate

"This ruling confirms our rights in this groundbreaking technology and re-establishes what we have been saying for years – that we have valuable solutions to support the advancement of dry battery electrode technology," said Joseph C. Bartolacci, President and Chief Executive Officer. "

Legal

Matthews Provides Update On Ongoing Business Dispute Involving Tesla; Says It Prevailed In Arbitration, Affirms Right To Sell Dry Battery Electrode Technology

Huntington Ingalls Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) reported quarterly earnings of $3.15 per share which missed the analyst consensus estimate of $3.31 by 4.83 percent. This is a 54.35 percent decrease over earnings of $6.90 per share from the same period last year. The company reported quarterly sales of $3.00 billion which missed the analyst consensus estimate of $3.05 billion by 1.65 percent. This is a 5.45 percent decrease over sales of $3.18 billion the same period last year.

Earnings

Earnings Misses

Huntington Ingalls Indus Q4 2024 GAAP EPS $3.15 Misses $3.31 Estimate, Sales $3.00B Miss $3.05B Estimate

Microsoft co-founder Bill Gates on Monday disclosed that he has donated $100 billion to charitable causes. 
What Happened: Despite Gates&#8217; extensive philanthropic efforts, he remains the world's seventh-richest person, with an estimated net worth of $164 billion, according to Bloomberg Billionaires.
In an interview with the <a href="https://www.bbc.com/news/articles/cx2p4p4l78zo">BBC</a>, he said philanthropy is now his primary focus and that giving away such a large sum has not impacted his personal lifestyle.
&#8220;I still have more to give,&#8221; he said, adding that &#8220;I&nbsp;will give away the vast&nbsp;majority of my money; it&#8217;s&nbsp;my full-time focus for the&nbsp;rest of my life, and&nbsp;I enjoy it.&#8221;
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/25/02/43518855/jeff-ubbens-valueact-bet-on-meta-visa-and-exited-spotify-in-q3-was-it-a-clever-move" target="_blank" rel="noreferrer noopener">Jeff Ubben's ValueAct Bet On Meta, Visa And Exited Spotify In Q3: Was It A Clever Move?</a>
He noted that the scale of his giving has not required any sacrifices, insisting that his daily life remains unchanged. &#8220;I didn&#8217;t&nbsp;order less hamburgers or less&nbsp;movies.&#8221;
Why It Matters: Had Gates retained the <a href="https://www.benzinga.com/news/24/07/39760110/bill-gates-has-20-years-more-to-give-away-his-billions-and-if-you-dont-like-it-he-wants-you-to-donat">$100 billion he has donated,</a> his total wealth would be around $264 billion, placing him second on the global wealth rankings behind Elon Musk and ahead of Jeff Bezos and Mark Zuckerberg. 
As of Wednesday&#8217;s market close, Gates&#8217; net worth ranks him two spots ahead of his longtime friend Warren Buffett, who is valued at $148 billion, and three spots above former Microsoft CEO Steve Ballmer, whose fortune stands at $144 billion.
His donations are part of a broader <a href="https://www.benzinga.com/news/24/08/40304161/bill-gates-and-warren-buffett-have-been-friends-for-decades-but-rising-tensions-now-threaten-their-p">pattern of billionaire philanthropy</a>, including Buffett, who has given tens of billions of dollars over the years. Gates co-founded the Giving Pledge in 2006 alongside Buffett and Melinda French Gates to encourage other ultra-wealthy individuals to commit the majority of their fortunes to charitable efforts.
Gates, who released his memoir Source Code: My Beginnings this week, has previously <a href="https://www.benzinga.com/24/12/42622967/bill-gates-answers-why-he-doesnt-just-voluntarily-pay-more-in-taxes-people-pay-taxes-as-an-obligation-of-law-not-out-of-charity">advocated for higher taxes </a>on the ultra-wealthy, arguing that people like him should have about a third of their current wealth.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43518087/official-trump-coin-jumps-427-but-still-75-below-januarys-all-time-high" target="_blank" rel="noreferrer noopener">TRUMP Meme Coin Jumps 4.27%, Outpaces Bitcoin, Ethereum And Dogecoin, But It's Still No Where Near January Highs</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Bill Gates Says He Donated $100 Billion Of His Wealth For Charitable Causes, But He 'Didn't Order Less Hamburgers Or Less Movies'

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

IREN

IREN Mined 521 BTC In Jan. vs 529 In Dec.

Barclays analyst Lauren Lieberman maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Overweight and lowers the price target from $158 to $153.

Barclays Maintains Overweight on PepsiCo, Lowers Price Target to $153

Piper Sandler analyst Biren Amin maintains Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Overweight and lowers the price target from $74 to $71.

VKTX

Piper Sandler Maintains Overweight on Viking Therapeutics, Lowers Price Target to $71

CCLD

CareCloud Announced That It Has Successfully Completed A SOC 2 Type 2 Examination For The Second Consecutive Year, Receiving A Clean Report With No Exceptions

<ul>
<li>Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial.</li>
<li>Data presented at AACR 2023 supports dual-targeting potential of IMM-1-104 in combination with anti-PD-1.</li>
</ul>

Contracts

IMRX

REGN

Immuneering Announced A Clinical Supply Agreement With Regeneron Pharmaceuticals For Libtayo (Cemiplimab)

Membership Int Ser 1971 Godfather Screenplay

Comments

ニュース

最新ニュース (OTC:RGFSS) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル